Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | AMT-116 |
| Synonyms | |
| Therapy Description |
AMT-116 is an antibody-drug conjugate (ADC) targeting CD44v9 conjugated to a topoisomerase I inhibitor, which potentially induces antitumor activity (J Clin Oncol 42, 2024 (suppl 16; abstr e15010)). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| AMT-116 | AMT116|AMT 116 | AMT-116 is an antibody-drug conjugate (ADC) targeting CD44v9 conjugated to a topoisomerase I inhibitor, which potentially induces antitumor activity (J Clin Oncol 42, 2024 (suppl 16; abstr e15010)). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05725291 | Phase Ib/II | AMT-116 | AMT-116 in Patients With Selected Advanced Solid Tumors | Recruiting | USA | AUS | 1 |